Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Images
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Reviewers 2022
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Snippets
Special Article
Specialty Interface
Studies
Study Letter
Study Letters
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Review and Meta-Analysis
Systematic Reviews
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
Therapy Letters
View Point
Viewpoint
What’s new in Dermatology
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Images
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Reviewers 2022
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Snippets
Special Article
Specialty Interface
Studies
Study Letter
Study Letters
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Review and Meta-Analysis
Systematic Reviews
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
Therapy Letters
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF

Translate this page into:

Case Letter
90 (
3
); 353-355
doi:
10.25259/IJDVL_1090_2022
pmid:
37317751

Rapid progression of cutaneous T-cell lymphoma in a patient with erythroderma during dupilumab treatment, following prior sequential azathioprine, baricitinib and cyclosporine treatments

Department of Dermatology, National Taiwan University Hospital, Zhongzheng Dist., Taipei, Taiwan

Corresponding author: Dr. Tsen-Fang Tsai, Department of Dermatology, National Taiwan University Hospital, No.7, Chung Shan S. Rd. Zhongshan S. Rd, Zhongzheng Dist., Taipei City, Taiwan tftsai@yahoo.com

Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Hsieh C-Y, Tsai T-F. Rapid progression of cutaneous T-cell lymphoma in a patient with erythroderma during dupilumab treatment, following prior sequential azathioprine, baricitinib and cyclosporine treatments. Indian J Dermatol Venereol Leprol. 2024;90:353-5. doi: 10.25259/IJDVL_1090_2022

Dear Editor,

Dupilumab is, in general, a well-tolerated medication indicated for the treatment of patients with atopic dermatitis. However, reports of progression or development of cutaneous T-cell lymphoma exist.1 Here, we report a patient diagnosed with erythrodermic atopic dermatitis who had rapid progression of mycosis fungoides with CD30+ large cell transformation during dupilumab treatment, following prior sequential treatment with azathioprine, baricitinib and cyclosporine.

A 34-year-old man with a family history of atopic diathesis presented to our clinic in 2017 with generalised itching, eczematous plaques and ichthyosis vulgaris since the age of eight [Figures 1a and 1b]. With suspicion of erythroderma due to atopic dermatitis, a biopsy was performed which showed psoriasiform epidermal hyperplasia with mild spongiosis, parakeratosis and small foci of Langerhans cell microgranulomas suggestive of spongiotic dermatitis. There was moderately dense band-like lymphocytic infiltration in the superficial dermis with scattered eosinophils. However, moderate lymphocyte exocytosis with focal nuclear atypia was present [Figure 2a].

(a and b) There were generalised erythematous, lichenified, excoriated plaques with brownish adherent scales on the legs. (c and d) After treatment with dupilumab, the skin lesions worsened. There were generalised, thick, erythematous, infiltrative plaques
Figure 1:
(a and b) There were generalised erythematous, lichenified, excoriated plaques with brownish adherent scales on the legs. (c and d) After treatment with dupilumab, the skin lesions worsened. There were generalised, thick, erythematous, infiltrative plaques
(a) Initial biopsy showed psoriasiform epidermal hyperplasia with mild spongiosis, parakeratosis, and small foci of Langerhans cell microgranuloma. Moderate lymphocyte exocytosis with focal nuclear atypia was also seen (H&E, 100x). (b) Repeat biopsy showed proliferation of sheets of large atypical lymphoid cells in the dermis with acanthosis (H&E, 100x)
Figure 2:
(a) Initial biopsy showed psoriasiform epidermal hyperplasia with mild spongiosis, parakeratosis, and small foci of Langerhans cell microgranuloma. Moderate lymphocyte exocytosis with focal nuclear atypia was also seen (H&E, 100x). (b) Repeat biopsy showed proliferation of sheets of large atypical lymphoid cells in the dermis with acanthosis (H&E, 100x)

The patient had failed various topical treatments and refused phototherapy. Due to concern of methotrexate toxicity, he was initially treated with azathioprine 100 mg daily in 2017 for 10 months in our clinic. Due to inadequate response, it was replaced with baricitinib 4 mg daily from January to August in 2018. Since April 2019, he is taking treatment from another hospital with cyclosporine 100–150 mg daily. Because of lack of improvement, the treatment drug was changed to dupilumab since January 2020. Nonetheless, gradual thickening of some pre-existing papules and plaques was noted after the drug switch [Figures 1c and 1d]. Skin biopsy was repeated in April 2020, and CD8+ mycosis fungoides was diagnosed based on the features of a lichenoid infiltrate of lymphocytes, histiocytes and eosinophils with epidermotropism. The lymphocytes were positive for CD3 and CD8, with a partial loss of CD7. Dupilumab was discontinued in April 2020, and he was treated with photochemotherapy, along with acitretin and methotrexate.

Despite the aforementioned treatments, biopsy performed in September 2020 revealed mycosis fungoides with large cell transformation [Figure 2b]. Upon examination, the patient had confluent erythema covering >80% of the body surface area. Whole body computer tomography showed axillary and inguinal lymphadenopathy, and biopsy revealed dermatopathic lymphadenopathy. Mycosis fungoides, T4N1M0B0, stage IIIA was confirmed. Chemotherapy with cyclophosphamide, etoposide, vincristine and prednisone (CEOP) was started since December 2020, which resulted in regression of axillary and inguinal lymphadenopathy. However, persistent scattered, infiltrative, erythematous plaques were noticed. Another biopsy in April 2022 revealed mycosis fungoides with CD30 expression in >80% of neoplastic cells. Thus, brentuximab vedotin was introduced since May 2022, and complete metabolic remission on 18F-FDG-PET scan was achieved in August 2022 without relapse until now.

Mycosis fungoides may mimic eczema, and an early diagnosis can be challenging. Usually, atopic dermatitis first appears in childhood, while mycosis fungoides has a much later onset. The diagnosis may be especially difficult in patients who present with erythrodermic mycosis fungoides and have an atopic diathesis. In our patient, an equivocal pathologic finding with atypical lymphocytes favouring dermatitis was reported. Among the oral agents used for the treatment of atopic dermatitis, methotrexate is also used for the treatment of cutaneous T-cell lymphoma. In contrast, increased risk of T-cell lymphoma was observed in patients with inflammatory bowel diseases on azathioprine,2 but no cases of cutaneous T-cell lymphoma have been reported in patients with atopic dermatitis, who were treated with either azathioprine or methotrexate.

The risk of lymphoma in patients with dupilumab has not been investigated in large-scale studies. Kołkowski et al. recently investigated the safety profiles of novel treatments for atopic dermatitis in the context of cutaneous T-cell lymphoma, and risks were observed only in patients treated with dupilumab and ruxolitinib, but not with other Janus kinase inhibitors such as baricitinib, upadacitinib and abrocitinib.3

The risk of cutaneous T-cell lymphoma in patients treated with dupilumab could be explained by several hypotheses. Dupilumab inhibits both IL-4 and IL-13 by targeting IL-4 receptor α (IL-4Rα). Blocking the IL-4Rα may paradoxically stimulate IL-13 signaling pathway via IL-13 receptor α2. IL-13 is associated with the pathogenesis and progression of various malignancies, including cutaneous T-cell lymphoma proliferation.4

It is worth noting that our patient had a long disease course since childhood, and his skin condition was either stable or was slightly improved from various agents that were considered to be “immunosuppressive,” including azathioprine, cyclosporine and baricitinib. Although dupilumab is considered a non-immunosuppressive agent, there was a rapid worsening of skin lesions after its introduction in 2020. Given the time sequence, rapid worsening of skin lesions after treatment and prior reports, dupilumab might have played an important role in the development of cutaneous T-cell lymphoma in the patient. However, methotrexate, azathioprine and cyclosporine were also related to the development of lymphoma or increased risk of lymphoma in patients with inflammatory bowel disease.5 Thus, the role of his preceding treatments, especially cyclosporine, in the development or progression of lymphoma cannot be totally excluded.

In our patient, it is likely that an early onset of erythrodermic mycosis fungoides was present as evidenced by the lack of adequate response to all systemic treatment of atopic dermatitis. In patients with erythroderma whose skin biopsy showed spongiotic dermatitis with suspicious atypical lymphocyte exocytosis, the use of systemic immunomodulators including dupilumab should be done with caution. Dermatologists should be familiar with the possibility of cutaneous T-cell lymphoma initiation or progression during the treatment of atopic dermatitis, especially in patients presenting with a sudden deterioration of existing lesions or the development of new eczematous plaques or lymphadenopathy. Further studies are warranted to investigate the possible immunopathogenic association between dupilumab and cutaneous T-cell lymphoma development.

Acknowledgement

We appreciated Dr. Yu-Chien Ko’s help for capturing the pathological slides.

Authors contributions

In this manuscript, Chang-Yu Hsieh contributed to the literature search, clinical studies, data acquisition, data and statistical analysis and manuscript preparation. Tsen-Fang Tsai contributed to the concepts, design, definition of intellectual content, experimental studies, and manuscript editing and review.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

  1. , , , , , , et al. Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients. J Am Acad Dermatol. 2020;83:197-9.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  2. , , , , , . T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: Results of the REFURBISH study. Am J Gastroenterol. 2013;108:99-105.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , . Safety and danger considerations of novel treatments for atopic dermatitis in context of primary cutaneous lymphomas. Int J Mol Sci. 2021;22:13388.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  4. , , . Comment on “Diagnostic testing of eczematous dermatitis with incomplete response to dupilumab”. J Am Acad Dermatol. 2022;87:e241-2.
    [CrossRef] [PubMed] [Google Scholar]
  5. , . Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Exp Rev Clin Immunol. 2010;6:621-31.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]

Fulltext Views
1,847

PDF downloads
1,085
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections